McKesson Corporation
McKesson Corp is a healthcare distribution and services company that moves branded, generic, specialty, biosimilar, and OTC medicines through large-scale pharmaceutical logistics networks. It also provides medical-surgical supply distribution, pharmacy technology, specialty health services, and market-access support, with major operations in the United States and Canada.
Fiscal year 2026 · change from previous year
Development 2021–2026
Business
Share of revenueDistribution and logistics for prescription drugs and related healthcare products across retail, institutional and specialty channels.
Medical-supply distribution, logistics, biomedical maintenance and support services for alternate-site providers.
Pharmaceutical wholesale, retail pharmacy, specialty health services and market-access solutions in Canada and Norway.
Technology-enabled pharmacy workflow, inventory, ordering and automation solutions for pharmacy customers.
Customers
McKesson sells primarily to pharmacies, hospitals, health systems, long-term care providers, oncology and other specialty practices, and other healthcare providers that need reliable drug and supply fulfillment. It also serves pharmaceutical manufacturers and biopharma partners that use McKesson for distribution, patient support, specialty services and market access. In Canada, it reaches retail pharmacies and institutional customers through wholesale distribution and a large pharmacy banner network.
National and regional chains, mail-order pharmacies and mass merchandisers buy high-volume pharmaceutical distribution, central fill and inventory solutions to improve replenishment speed and cost efficiency.
Independent and small-to-medium chain pharmacies buy generics, ordering systems, inventory tools and merchandising programs to improve cash flow and profitability.
Hospitals, health systems, integrated delivery networks and long-term care providers buy pharmaceuticals and medical-surgical supplies to support patient care operations.
Oncology, specialty and biopharma-related practices buy specialty drug distribution, patient support and logistics services for complex therapies.
Manufacturers use McKesson for distribution, logistics, market access and specialty services to reach providers and patients efficiently.
Strategy
McKesson is focused on scaling its core pharmaceutical distribution franchise, expanding specialty and biopharma services, and improving operating efficiency through automation and technology. The company is also reshaping its portfolio through divestitures and separations, including the planned separation of Medical-Surgical Solutions and the exit from non-core international assets. Acquisitions such as PRISM Vision and Core Ventures show a push to broaden specialty healthcare services and deepen customer relationships.
Specialty therapies are higher-touch and can deepen customer relationships beyond commodity distribution.
Distribution is a low-margin business, so automation and process discipline protect service levels and margins.
Separating non-core assets can improve strategic focus and capital allocation.
Geography
McKesson is heavily concentrated in the United States, where its pharmaceutical and medical-surgical networks operate through 27 distribution centers and serve the majority of its customer base. Internationally, the company has operations in Canada and a smaller remaining presence in Norway, while it has largely exited other European markets. Geography matters because regulatory regimes, drug pricing, healthcare channel mix and divestiture activity differ materially across these markets.
Risks
McKesson faces litigation, regulatory and reimbursement risk because it operates in highly regulated drug distribution and has been exposed to opioid-related claims and other legal disputes. Its low-margin, high-volume model also depends on uninterrupted logistics, supplier relationships and cybersecurity resilience, while goodwill and acquisition accounting can create future impairment risk if growth assumptions weaken. Changes in drug mix, brand-to-generic conversion, inflation and government actions can quickly affect profitability.
- Litigation and opioid-related claimsImpact: HighLikelihood: High
The company has recorded charges for estimated opioid-related liabilities and continues to face legal disputes.
Exposure - Cybersecurity incidentsImpact: HighLikelihood: High
McKesson handles protected health information and critical logistics systems that are attractive targets for cyberattacks.
Exposure - Regulatory and pricing pressureImpact: HighLikelihood: High
Drug distribution and pharmacy services are exposed to healthcare regulation, reimbursement changes and government actions.
Exposure - Goodwill and long-lived asset impairmentImpact: MediumLikelihood: Medium
Acquisitions and portfolio changes require judgment on future cash flows and fair values.
Exposure
Accounting
Judgemental itemsManagement estimates legal exposure and records charges when probable and estimable, which can materially affect earnings and cash needs.
Impact: Can create large, non-recurring expense and liability swings
U.S. pharmaceutical gross profit is sensitive to inflation and inventory cost layers under LIFO.
Impact: Can move gross margin up or down with drug price inflation
The company tests goodwill annually and when indicators arise; weaker cash flow assumptions could trigger impairment.
Impact: Potential non-cash write-downs in future periods
Portfolio exits, separations and restructuring initiatives create charges, remeasurement gains and comparability noise.
Impact: Affects operating profit and period-to-period comparability
Similar listed companies
Publicly listed companies with a comparable business focus.
Gilead Sciences, Inc
GILD · Biological Products, (No Diagnostic Substances)
Gilead Sciences is a U.S.-based biopharmaceutical company focused on discovering, developing, and commercializing medicines for serious diseases.
Bio Essence Corp
BIOE · Pharmaceutical Preparations
Bio Essence Corp is a California-based holding company whose operating history has centered on health supplements and OEM manufacturing/distribution services.
GSK plc
GSK · Pharmaceutical Preparations
GSK plc is a global biopharma company that develops and commercializes prescription medicines, vaccines, and specialty treatments.
Biogen Inc
BIIB · Biological Products, (No Diagnostic Substances)
Biogen is a U.S.-based biopharmaceutical company built around therapies for serious neurological, immunological and rare diseases.
Bristol-Myers Squibb Company
BMY · Pharmaceutical Preparations
Bristol Myers Squibb is a U.S.-based biopharmaceutical company that discovers, develops, manufactures, markets, and sells innovative medicines for serious diseases.
Medpace Holdings, Inc.
MEDP · Services-Commercial Physical & Biological Research
Medpace Holdings is a contract research organization that runs outsourced clinical development programs for biotechnology, pharmaceutical, and medical device companies.
Last updated: 24/09/2026